Janux Therapeutics, Inc. upgraded to Strong Buy: below cash value, strong runway, TRACTr progress, Merck/BMY milestones.
Andrew Sather, co-host of The Investing for Beginners Podcast, recently warned listeners that share dilution has quietly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results